Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Alejandro Rabinstein
Evaluation of the Effect of Sodium–glucose Co‐transporter 2 Inhibition With Empagliflozin on Morbidity and Mortality of Patients With Chronic Heart Failure and a Reduced Ejection Fraction: Rationale for and Design of the EMPEROR‐Reduced Trial
European Journal of Heart Failure
Cardiovascular Medicine
Cardiology
Evaluation of the Effects of Sodium–glucose Co‐transporter 2 Inhibition With Empagliflozin on Morbidity and Mortality in Patients With Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR‐Preserved Trial
European Journal of Heart Failure
Cardiovascular Medicine
Cardiology
An Assessment of the Incremental Value of the ABCD2 Score in the Emergency Department Evaluation of Transient Ischemic Attack
Annals of Emergency Medicine
Emergency Medicine
Is a Second Cycle of Immunoglobulin Justified in Axonal Forms of Guillain-Barré Syndrome?
Arquivos de Neuro-Psiquiatria
Biological Psychiatry
Neurology
The Triglyceride Paradox in Stroke Survivors: A Prospective Study
Neuroscience Journal
Related publications
Neuropsychiatric Outcomes After Stroke – Authors' Reply
The Lancet Neurology
Neurology
Maximising the Value of Research for Brain Health
The Lancet Neurology
Neurology
Cannabidiol in Patients With Treatment-Resistant Epilepsy
The Lancet Neurology
Neurology
WHO Takes Up the Baton on Dementia
The Lancet Neurology
Neurology
Learning About the Brain With Comics
The Lancet Neurology
Neurology
Functional (Psychogenic) Saccadic Oscillations and Oculogyric Crises – Authors' Reply
The Lancet Neurology
Neurology
Dream Weaver
The Lancet Neurology
Neurology
The Evolution of Universally Accessible Building Design
The Lancet Neurology
Neurology
Global, Regional, and National Burden of Meningitis, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016
The Lancet Neurology
Neurology
Intravenous Immunoglobulin for Treatment of Mild-To-Moderate Alzheimer's Disease: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Trial
The Lancet Neurology
Neurology
